NCT05798013

Brief Summary

The purpose of this study is to evaluate the effectiveness of digital health management for intervention on Chinese population with head and neck vascular stenosis.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
102,072

participants targeted

Target at P75+ for not_applicable

Timeline
30mo left

Started Oct 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress20%
Oct 2025Oct 2028

First Submitted

Initial submission to the registry

March 22, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 4, 2023

Completed
2.5 years until next milestone

Study Start

First participant enrolled

October 1, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2028

Last Updated

October 2, 2024

Status Verified

October 1, 2024

Enrollment Period

2 years

First QC Date

March 22, 2023

Last Update Submit

October 1, 2024

Conditions

Keywords

head and neck vascular stenosisdigital health management

Outcome Measures

Primary Outcomes (1)

  • New-onset stroke events at 24 months

    New-onset stroke events include ischemic stroke, transient ischemic attack, and hemorrhagic stroke.

    24 months

Secondary Outcomes (3)

  • New-onset stroke events at 12 months

    12 months

  • Composite and separate indicators of new clinical vascular events at 12 and 24 months

    12 months, 24 months

  • All-cause deaths at 24 months

    24 months

Study Arms (2)

Digital health management intervention Group

EXPERIMENTAL

Patients in the trial group receives intervention management from the digital health management platform, including reminding patients to take medication on time, monitoring and managing risk factors, reminding patients to have regular checkups and regular follow-ups, and pushing personalized science based on patients' risk factors, etc. Meanwhile, the platform's customer service staff regularly follows up with patients and reminds them of health management, and regularly invites experts to conduct formal medical science conferences for patients.

Behavioral: Digital health management

Control group

NO INTERVENTION

The group doesn't not receive intervention reminders and customer service supervision from the platform, but receives the same follow-up visits.

Interventions

The digital health management platform mainly includes reminding patients to take medication on time, monitoring and managing risk factors, reminding patients of regular review and regular follow-up, pushing personalized science according to patients' risk factors, etc., as well as following up and supervising patients' health management, and conducting regular formal medical science conferences.

Digital health management intervention Group

Eligibility Criteria

Age35 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Hospitals with the qualification of "head and neck ultrasound center" in China.
  • (1)Age ≥ 35 years old, with no restriction on gender.
  • (2)Patients with clinically diagnosed head and neck stenosis or occlusion, including mild, moderate or severe stenosis or occlusion of the carotid artery and mild, moderate or severe stenosis or occlusion of the intracranial artery.
  • (3)Ability to use a smartphone and have a mobile application installed on the handset.
  • (4)Subjects or their legal representatives agreed to the study and signed the project informed consent form.

You may not qualify if:

  • The included centers did not have the capacity to undertake the trial.
  • (1)Combination of severe systemic diseases such as respiratory failure, renal failure, gastrointestinal bleeding, coagulation dysfunction, malignancy, etc.
  • (2)Patients with a life expectancy of less than 2 years or who are unable to complete the study for other reasons.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

First Hospital of Jilin University

Changchun, Jilin, 130000, China

Location

Central Study Contacts

Yi Yang, MD, PhD

CONTACT

Zhenni Guo, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associated Dean of First Hospital of Jilin University

Study Record Dates

First Submitted

March 22, 2023

First Posted

April 4, 2023

Study Start

October 1, 2025

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

October 1, 2028

Last Updated

October 2, 2024

Record last verified: 2024-10

Locations